Cancer Centre, University Hospital of North Midlands, Staffordshire, United Kingdom
*Corresponding Author: Shahid Gilani, Cancer Centre, University Hospital of North Midlands, Staffordshire, United Kingdom.
Received: August 31, 2020; Published: October 01, 2020
Cancer patients have increased risk of venous thromboembolism (VTE) as well as bleeding. For many years Low Molecule Heparin (LMHW) remained standard of care for treatment of cancer associated thrombosis (CAT). Recently Direct Oral Anticoagulants (DOACs) have shown similar efficacy and safety in large randomised control trials. Data from four recent trials done in cancer patients have highlighted importance of DOACs in these patients. DOACs are found simpler to administer with better compliance among these patients. However, there are several issues surrounding prescribing DOACs in cancer patients. Some of them are related to drug-to-drug interactions and others to increased risk of bleeding in mucosal cancers of gastrointestinal (GI) and urothelial tracts. In this review, author summarised and updated clinical information and compiled easy to use practical guide for treatment of VTE in cancer patients in flow-sheet manner. It is also suggested to establish a multidisciplinary cancer associated thrombosis clinic for these patients for long term follow-up.
Keywords: Venous Thromboembolism (VTE); Low Molecule Heparin (LMHW); Cancer Associated Thrombosis (CAT); Direct Oral Anticoagulants (DOACs); Gastrointestinal (GI); Deep Vein Thrombosis (DVT); Pulmonary Embolism (PE)
Citation: Shahid Gilani. “Direct Oral Anticoagulants (DOACs) in Cancer Related Thromboembolism".Acta Scientific Cancer Biology 4.10 (2020): 07-15.
Copyright: © 2020 Shahid Gilani. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.